An approach for half‐life extension and activity preservation of an anti‐diabetic peptide drug based on genetic fusion with an albumin‐binding aptide
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2017.04.036
Abstract: Abstract Although the peptide, exenatide, has been widely used as a drug for the treatment of type 2 diabetes, its short plasma half‐life requires frequent subcutaneous injection, resulting in poor patient compliance in addition to… read more here.
Keywords: fusion; fusion peptide; exenatide apthsa; half life ... See more keywords